Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

Clinical trial NCT05366218 · RECRUITING

Trial details

NCT number: NCT05366218
Sponsor: University Hospital Tuebingen
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

ALL, Childhood B-Cell Acute Lymphoid Leukemia Relapse Acute Lymphocytic Leukemia Refractory

Start date: 2023-03-08
Primary completion: 2028-07-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.